Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
5.01
Dollar change
+1.52
Percentage change
43.55
%
Index- P/E- EPS (ttm)-1.06 Insider Own- Shs Outstand85.82M Perf Week121.68%
Market Cap571.14M Forward P/E- EPS next Y-0.84 Insider Trans- Shs Float- Perf Month139.71%
Income-81.89M PEG- EPS next Q-0.23 Inst Own0.64% Short Float- Perf Quarter129.82%
Sales7.71M P/S74.08 EPS this Y5.60% Inst Trans18.29% Short Ratio0.51 Perf Half Y105.33%
Book/sh5.01 P/B1.00 EPS next Y14.99% ROA-11.54% Short Interest0.81M Perf Year-20.48%
Cash/sh0.68 P/C7.36 EPS next 5Y48.80% ROE-16.40% 52W Range1.61 - 10.24 Perf YTD127.73%
Dividend Est.- P/FCF- EPS past 5Y-7.89% ROI-13.22% 52W High-51.07% Beta3.51
Dividend TTM- Quick Ratio2.71 Sales past 5Y5.23% Gross Margin-245.38% 52W Low211.18% ATR (14)0.45
Dividend Ex-Date- Current Ratio2.71 EPS Y/Y TTM20.32% Oper. Margin-940.78% RSI (14)81.13 Volatility25.79% 11.93%
Employees83 Debt/Eq0.24 Sales Y/Y TTM-24.47% Profit Margin-1061.43% Recom1.80 Target Price8.76
Option/ShortYes / No LT Debt/Eq0.22 EPS Q/Q10.96% Payout- Rel Volume8.81 Prev Close3.49
Sales Surprise-12.43% EPS Surprise10.43% Sales Q/Q-3.91% EarningsFeb 28 AMC Avg Volume1.59M Price5.01
SMA20108.09% SMA50139.23% SMA20043.23% Trades Volume14,032,270 Change43.55%
Date Action Analyst Rating Change Price Target Change
Aug-31-23Upgrade Jefferies Hold → Buy
Aug-07-23Downgrade Maxim Group Buy → Hold
Aug-04-23Downgrade William Blair Outperform → Mkt Perform
Aug-04-23Downgrade Piper Sandler Overweight → Neutral $7 → $2
Mar-09-23Initiated William Blair Outperform $8
Dec-06-22Downgrade Jefferies Buy → Hold
Sep-06-22Initiated Piper Sandler Overweight $7
Apr-07-21Upgrade Maxim Group Hold → Buy $18
Dec-22-20Downgrade Maxim Group Buy → Hold
Dec-04-20Downgrade Chardan Capital Markets Neutral → Sell $7.50
Mar-27-24 11:00AM
Mar-25-24 10:34PM
Mar-24-24 07:55AM
Mar-13-24 07:30PM
Mar-10-24 07:54PM
08:25AM Loading…
Mar-03-24 08:25AM
Feb-28-24 05:57PM
Feb-26-24 07:00AM
Feb-14-24 07:46PM
Jan-30-24 09:13PM
Jan-19-24 11:30AM
Jan-18-24 06:36PM
Nov-27-23 07:28AM
Nov-26-23 06:56PM
Nov-21-23 06:32PM
08:04PM Loading…
Oct-30-23 08:04PM
Sep-26-23 06:18AM
Sep-22-23 04:59PM
Sep-21-23 03:30AM
Aug-30-23 07:07PM
Aug-29-23 07:00AM
Aug-04-23 09:38AM
Aug-03-23 08:10PM
Jul-30-23 08:31PM
Jun-04-23 08:21PM
May-25-23 07:28PM
May-24-23 07:00AM
Apr-27-23 09:00PM
Apr-25-23 08:47PM
Mar-21-23 09:20PM
07:03PM Loading…
Mar-07-23 07:03PM
Feb-27-23 05:13PM
04:49PM
Feb-26-23 07:38PM
Feb-16-23 06:16PM
Feb-08-23 06:09PM
Jan-31-23 06:30PM
04:40AM
Dec-22-22 07:18PM
Dec-15-22 12:00PM
Dec-02-22 03:13PM
Nov-23-22 09:38AM
Nov-22-22 06:32PM
06:01PM
Nov-21-22 06:00AM
Oct-30-22 07:50PM
Oct-02-22 07:52PM
Aug-30-22 07:05PM
Aug-29-22 08:14PM
Aug-18-22 07:00AM
Jul-29-22 07:05AM
Jul-11-22 08:40PM
Jun-28-22 11:54PM
Jun-23-22 12:05PM
Jun-20-22 12:06PM
Jun-09-22 07:00AM
May-31-22 08:15PM
May-08-22 08:15PM
May-05-22 08:40PM
Apr-28-22 08:35PM
Apr-13-22 10:25AM
Mar-28-22 09:30PM
Mar-23-22 08:40PM
Feb-27-22 05:18PM
Feb-24-22 05:30PM
05:57AM
Feb-20-22 06:19PM
Feb-01-22 07:20PM
Jan-30-22 07:16PM
Jan-24-22 06:45PM
Jan-11-22 08:26PM
Dec-30-21 06:38PM
Dec-15-21 07:09PM
10:00AM
Dec-13-21 07:18PM
Dec-05-21 06:47PM
Dec-02-21 04:57PM
Dec-01-21 10:00AM
Nov-29-21 10:00AM
Nov-23-21 06:09PM
07:18AM
Nov-22-21 06:51AM
Nov-21-21 07:31PM
Nov-14-21 07:13PM
Oct-28-21 07:51PM
Oct-18-21 08:00AM
Oct-06-21 08:38PM
Aug-30-21 07:38PM
08:00AM
Aug-24-21 09:13PM
Jul-29-21 08:06PM
Jul-19-21 06:45AM
Jul-18-21 08:58PM
Jul-15-21 08:15PM
Jul-01-21 07:21AM
Jun-30-21 07:46PM
Jun-25-21 02:23PM
Jun-02-21 08:01PM
06:01PM
May-25-21 07:00AM
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.